Industry Updates
This broad category includes articles concerning health insurance costs, carrier and health plan news, changing benefits technology, and surveys by the Kaiser Family Foundation and others on employee benefits.
State legislators and advocates are racing to get federal approval in the waning months of the Obama administration for a proposal to allow immigrants living in the U.S. illegally onto the California insurance exchange.
Bolstered by the federal health care reform law, the number of low-income kids getting full health coverage in California continues to grow, as it does in the nation as a whole, a recent study found.
A Centers for Disease Control and Prevention survey shows California's uninsured rate is down to 8.1 percent.
President Barack Obama’s administration is approving California’s plan to restructure health-plan taxes to generate money for Medi-Cal, which provides health coverage to the poor.
A California law that kicks in Monday makes immigrant children without legal documentation eligible for comprehensive, government-paid health care.
California’s health insurance exchange estimates that its Obamacare premiums may rise 8 percent on average next year, which would end two consecutive years of more modest 4 percent increases.
Health insurers and patients could safely save many billions of dollars annually by swapping out a more expensive drug for a less expensive generic in the same class of drugs, according to a study published Monday.
The Department of Health and Human Services (HHS) is tightening the rules for certain SEPs and clarifying that SEPs are only available in six defined and limited types of circumstances. Please read below for details regarding the new rules being implemented.
Insurers will seek significant premium hikes under President Barack Obama’s health care law this summer — stiff medicine for consumers and voters ahead of the national political conventions.
Health insurers and patients could safely save many billions of dollars annually by swapping out a more expensive drug for a less expensive generic in the same class of drugs, according to a study published Monday.